Anxiety suppression (also known as anxiolysis or minimal sedation) is medically recognized as a partial to complete suppression of a person’s ability to feel anxiety, general unease, and negative feelings of both psychological and physiological tension. The experience of this effect may decrease anxiety-related behaviours such as restlessness, muscular tension, rumination, and panic attacks. Complete anxiety suppression can produce feelings of extreme calmness and relaxation; however, it can also lead to undesirable outcomes when accompanied by other effects such as disinhibition or sedation.
It is most commonly induced under the influence of moderate dosages of anxiolytic compounds which primarily include GABAergic depressants, such as benzodiazepines, alcohol, GHB, and gabapentinoids. However, it can also occur to a lesser extent under the influence of a large variety of other pharmacological classes which include but are not limited to cannabinoids, dissociatives, SSRIs, and opioids.
Compounds within our psychoactive substance index which may cause this effect include:
- Amanita muscaria
Anecdotal reports which describe this effect within our experience index include:
- Experience: 36mg 4-AcO-DiPT - Truly, one for the psychedelic animals among us
- Experience: 660ug LSD - First bad trip
- Experience:100 mg- Actually Lifechanging
- Experience:120µg LSD - First Bad Acid Trip, Psychosis
- Experience:150mg MDMA + 20mg 2C-B - I designed it this way myself
- Experience:20mg (insufflated) - permanent all-encompassing states of unity and interconnectedness
- Experience:20mg Etizolam - Smoking Etizolam
- Experience:225mg Pregabalin +Cannabis -Bliss and Serenity; a hedonistic evening
- Experience:25mg 2C-B - Hard raving at home
- Experience:25mg Quetiapine - Nice buzz
- Experience:260 mg Ketamine (insufflated) - Lost in Paisley
- Experience:2C-P (approx. 35mg) - Asymmetrical Terror and the Geometric Sea
- Experience:2mg 25C-NBOMe - Experimental trip to test personal limits of NBOMes
- Experience:2mg Etizolam - Here be dragons
- Experience:3 bowls of cannabis indica - I wrote down unintelligible gibberish
- Experience:3-MMC: Weak substitute? No way!
- Experience:3.5g psilocybe cubensis - Relinquishing of Material Chains/Fear and Desolation
- Experience:300mg DXM + 25mg DMT + Cannabis - A crazy night
- Experience:300ug LSD - Profound religious experience
- Experience:300µg LSD - Togetherness and the Silent Dusk
- Experience:3mg Etizolam - A Comedown Drug
- Experience:40mg Zolpidem / 20mg Diazepam - Please Don't Do This
- Experience:60mg 4-AcO-DMT Nonstop Quasi-Orgasmic Objectless Euphoria
- Experience:60mg Zolpidem - A Delirious Adventure
- Experience:7500mg - Analysis of gabapentin
- Experience:800 seeds LSA - My First Trip Ever
- Experience:An experiement combining mangoes and cannabis
- Experience:BK-2C-B - Various experiences
- Experience:DXM and Cannabis: 100mg - Unexpected Strong Trip
- Experience:Datura and nicotine smoked - 4 and ~15 hits; was actually quite pleasant
- Experience:Diazepam (20/10mg, Oral) - Comfortably Drunk
- Experience:Kratom + Phenibut + Cannabis - Warm Bliss
- Experience:MXE: 37.5 mg - Calm and Cloudy Bliss
- Experience:Mushrooms (~0.5 g) - Autonomous Voice
- Experience:Nightmare flipping
- Experience:Psilocybin Mushroom (0.16 g, Oral) - Dosage Independent Intensity
- Experience:Zopiclone hppd?
- Experience:~150mg MDA(oral) - a case of mistaken identity
- Responsible use
- Subjective effects index
- Psychedelics - Subjective effects
- Dissociatives - Subjective effects
- Deliriants - Subjective effects
- ↑ anxiolysis, National Cancer Institute
- ↑ Gordon, Joshua A. (2002). "Anxiolytic drug targets: beyond the usual suspects". Journal of Clinical Investigation. 110 (7): 915–917. doi:10.1172/JCI0216846. ISSN 0021-9738.
- ↑ Tyrer, P. (27 February 1988). "Prescribing psychotropic drugs in general practice". BMJ. 296 (6622): 588–589. doi:10.1136/bmj.296.6622.588.
- ↑ Lydiard, R. B. (2003). "The role of GABA in anxiety disorders". The Journal of Clinical Psychiatry. 64 Suppl 3: 21–27. ISSN 0160-6689.
- ↑ Gauthier, Isabelle; Nuss, Philippe (2015). "Anxiety disorders and GABA neurotransmission: a disturbance of modulation". Neuropsychiatric Disease and Treatment: 165. doi:10.2147/NDT.S58841. ISSN 1178-2021.
- ↑ Wood, Alastair J.J.; Shader, Richard I.; Greenblatt, David J. (1993). "Use of Benzodiazepines in Anxiety Disorders". New England Journal of Medicine. 328 (19): 1398–1405. doi:10.1056/NEJM199305133281907. ISSN 0028-4793.
- ↑ Smith, J. P., Randall, C. L. (2012). "Anxiety and alcohol use disorders: comorbidity and treatment considerations". Alcohol Research: Current Reviews. 34 (4): 414–431. ISSN 2168-3492.
- ↑ Schmidt-Mutter, Catherine; Pain, Laure; Sandner, Guy; Gobaille, Serge; Maitre, Michel (1998). "The anxiolytic effect of γ-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil". European Journal of Pharmacology. 342 (1): 21–27. doi:10.1016/S0014-2999(97)01503-3. ISSN 0014-2999.
- ↑ Pollack, Mark H.; Matthews, John; Scott, Erin L. (1998). "Gabapentin as a Potential Treatment for Anxiety Disorders". American Journal of Psychiatry. 155 (7): 992–993. doi:10.1176/ajp.155.7.992. ISSN 0002-953X.
- ↑ Blessing, Esther M.; Steenkamp, Maria M.; Manzanares, Jorge; Marmar, Charles R. (2015). "Cannabidiol as a Potential Treatment for Anxiety Disorders". Neurotherapeutics. 12 (4): 825–836. doi:10.1007/s13311-015-0387-1. ISSN 1933-7213.
- ↑ Irwin, Scott A.; Iglewicz, Alana (2010). "Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care". Journal of Palliative Medicine. 13 (7): 903–908. doi:10.1089/jpm.2010.9808. ISSN 1096-6218.
- ↑ (PDF) https://www.regionkronoberg.se/contentassets/7fd21479ae564476a1b8639e9519ede9/diazepam-hameln.pdf. Missing or empty